Search results
Showing 1 to 13 of 13 results for parathyroid hormone
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission.
Show all sections
Sections for TA625
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development [GID-TA11454] Expected publication date: TBC
Thoracoscopic excision of mediastinal parathyroid tumours (IPG247)
Evidence-based recommendations on thoracoscopic excision of mediastinal parathyroid tumours. This involves operating on the tumour using a flexible camera inserted through small cuts in the chest (keyhole surgery).
View recommendations for IPG247Show all sections
Sections for IPG247
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Minimally invasive video‑assisted parathyroidectomy (IPG501)
Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Healthy start vitamins: special report on cost effectiveness (ECD5)
Healthy start vitamins: special report on cost effectiveness
Difelikefalin for treating pruritus in people having haemodialysis (TA890)
Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis.